Clinical trials have demonstrated the efficacy of Lorlatinib in patients with ALK-positive NSCLC who have previously been treated with one or more ALK inhibitors. Studies such as the Phase II trial showed a significant overall response rate, including complete and partial responses. The progression-free survival and overall survival rates were also favorable compared to patients who did not receive Lorlatinib.
